Posted by Michael Wonder on 05 Feb 2022
Price of COVID treatments from Pfizer, Merck, GSK align with patient benefits
3 February 2022 - The prices of drugs used to treat COVID-19 for those at risk of serious illness are "reasonably aligned" with how much they help patients, according to a draft report from drug pricing research organisation ICER.
The report assessed Pfizer's Paxlovid and Merck's molnupiravir - both recently authorised anti-viral pills - as well as sotrovimab, an intravenous monoclonal antibody drug developed by GSK and Vir Biotechnology.
